The firm raised €4.7 million through a conditional placement, and €5.0 million through an unconditional direct subscription.
Earlier this month, Angle placed about 34.8 million new ordinary shares at 35 pence per share, grossing £12.2 million.
The firm, which said last week it expected to raise $15.9 million, has said it will use the net proceeds for working capital and general corporate purposes.
The company said it plans to use the net proceeds for working capital and general corporate purposes.
The offer of $402 per share was made in connection with Abbott's acquisition of Alere, which was completed on Tuesday.
The company said it plans to use the proceeds raised in the private placement primarily to fund its Hodgkin's lymphoma test clinical trial.
The company will use the net proceeds to finance its current operations and expand its US commercialization capacities for its lead product, Epi proColon.
The company said it will use the proceeds from the offering for working capital and general corporate purposes, among other things.
The shelf registration follows a recent $56.5 million financing and comes amid an expansion of the firm's commercial operations.
The company said it would use the proceeds of the offering to promote its genetic tests and services, among other things.
New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.
Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.
La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.
In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.